IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 176-200 out of 1247.

<< < 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 > >>

Public Release: 28-Sep-2014
Nature Medicine
Researchers identify early sign of pancreatic cancer
Scientists at Dana-Farber Cancer Institute, the Massachusetts Institute of Technology, and other institutions have discovered a sign of the early development of pancreatic cancer -- an upsurge in certain amino acids that occurs before the disease is diagnosed and symptoms appear. The research is being published online today by the journal Nature Medicine.
The Howard Hughes Medical Institute, Lustgarten Foundation, National Institutes of Health, Nestle Research Center, Robert T. and Judith B. Hale Fund for Pancreatic Cancer, Perry S. Levy Fund

Contact: Anne Doerr
anne_doerr@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute

Public Release: 28-Sep-2014
ESMO 2014 Congress
Annals of Oncology
Under-representation of women in oncology leadership positions
A growing number of oncologists in Greece are female, but women continue to be under-represented in leadership positions, according to a survey reported at the ESMO 2014 Congress.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 28-Sep-2014
ESMO 2014 Congress
Annals of Oncology
Pertuzumab adds 16 months survival benefit to trastuzumab and chemo treatment for HER2-positive breast cancer
Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 28-Sep-2014
ESMO 2014 Congress
Annals of Oncology
IMPRESS trial data on continuing tyrosine kinase inhibitor therapy after resistance development in lung cancer reported
Patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy, a phase III trial presented at the ESMO 2014 Congress has shown.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 28-Sep-2014
ESMO 2014 Congress
Annals of Oncology
Many patients lack information about the use of targeted therapies, oncologists say
More than three quarters of oncology specialists in Europe, South America and Asia believe their patients are not always well enough informed about the treatment options available to them, survey results have revealed at the ESMO 2014 Congress in Madrid, Spain.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 28-Sep-2014
ESMO 2014 Congress
Annals of Oncology
Adding cediranib to chemo improves progression-free survival for meta or recurrent cervical cancer
For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 27-Sep-2014
ESMO 2014 Congress
Annals of Oncology
Afatinib improves progression-free survival in head and neck cancer
The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a Phase III trial show.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 27-Sep-2014
ESMO 2014 Congress
New England Journal of Medicine
Crizotinib treatment effective against ROS1-positive lung cancer
Treatment with the targeted therapy drug crizotinib effectively halted the growth of lung tumors driven by rearrangements of the ROS1 gene in a small clinical trial.
Pfizer, NIH/National Cancer Institute, Uniting Against Lung Cancer, Swedish Research Council, Be a Piece of the Solution

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital

Public Release: 27-Sep-2014
ESMO 2014 Congress
Annals of Oncology
Rolapitant reduces nausea and vomiting in Phase III trial
Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to the results of a Phase III trial presented for the first time today at the ESMO 2014 Congress in Madrid, Spain.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 27-Sep-2014
ESMO 2014 Congress
Annals of Oncology
Cancer during pregnancy: Chemotherapy and radiotherapy are safe for babies, studies show
Children who are exposed to chemotherapy or radiotherapy while in the womb suffer no negative impacts on mental or cardiac development, international studies presented at the ESMO 2014 Congress in Madrid have shown.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 27-Sep-2014
ESMO 2014 Congress
Annals of Oncology
Anamorelin improve appetite and body mass in patients with cancer anorexia-cachexia
A new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 27-Sep-2014
Science
Evolutionary biology: It's not just for textbooks anymore
UA scientists, including entomology expert Bruce Tabashnik, are on the leading edge of an approach to tackle global challenges in food security, emerging diseases and biodiversity loss.
National Science Foundation, NIH/National Institute of General Medical Sciences, Maine Agricultural and Forest Experiment Station, National Research Centre for Growth and Development, Commonwealth Scientific and Industrial Research Organisation, others

Contact: Daniel Stolte
stolte@email.arizona.edu
520-626-4402
University of Arizona

Public Release: 27-Sep-2014
ESMO 2014 Congress
Annals of Oncology
French studies measure benefits of colorectal cancer screening
The introduction of biennial colorectal cancer screening in a region of France increased the rate of diagnosis of high risk pre-cancerous adenomas -- sometimes called polyps -- by 89 percent, researchers have reported at the ESMO 2014 Congress in Madrid.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 27-Sep-2014
ESMO 2014 Congress
Annals of Oncology
Customising chemotherapy in Lu Ca: New Ph II data reported in 2 LB studies
Measuring the expression levels of an enzyme involved in DNA synthesis can help predict the response of lung cancers to certain treatments, a Korean study has shown at the ESMO 2014 Congress in Madrid.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 27-Sep-2014
ESMO 2014 Congress
Annals of Oncology
Docetaxel or pemetrexed with cisplatin achieve comparable outcomes in non-squamous Lu Ca
The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel was associated with more frequent adverse events.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 26-Sep-2014
ESMO 2014 Congress
Annals of Oncology
More than 70 percent of young oncologists in Europe suffer symptoms of burnout
Across Europe, more than 70 percent of young cancer specialists are showing signs of burnout, the largest survey of its kind has revealed. The results, reported at the Congress of the European Society for Medical Oncology in Madrid, have prompted calls for serious action to address the issue at all levels.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 26-Sep-2014
Nature Communications
Protein 'map' could lead to potent new cancer drugs
Imperial chemists have gained fresh insights into how a disease-causing enzyme makes changes to proteins and how it can be stopped.
Cancer Research UK, Biotechnology and Biological Sciences Research Council, Medical Research Council, The Engineering and Physical Sciences Research Council, European Union

Contact: Gail Wilson
gail.wilson@imperial.ac.uk
44-020-759-46702
Imperial College London

Public Release: 26-Sep-2014
ESMO 2014 Congress
Annals of Oncology
Discrepancies in access to new cancer drugs revealed
Access to potentially life-extending cancer drugs varies significantly in different regions of the world, two new studies show at the ESMO 2014 Congress in Madrid, Spain.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 26-Sep-2014
Angewandte Chemie International Edition
Strategy to reduce side effects in modern cancer therapy
An interdisciplinary team of researchers from the University of Vienna and the Medical University of Vienna has successfully developed a new strategy for reducing the often serious side effects of an important class of modern anticancer drugs -- tyrosine kinase inhibitors. The novel drug is supposed to restrict its activity with high selectivity to the malignant tumor.

Contact: Christian Kowol
christian.kowol@univie.ac.at
0043-142-775-2609
University of Vienna

Public Release: 26-Sep-2014
Journal of the National Cancer Institute
Many patients excluded from clinical trials due to prior cancer, UTSW study finds
Lung cancer clinical trials exclude a substantial proportion of patients due to a history of prior cancer, as shown in an analysis by cancer researchers at UT Southwestern Medical Center.

Contact: Lori Sundeen Soderbergh
lori.soderbergh@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center

Public Release: 25-Sep-2014
Clinical Gastroenterology and Hepatology
Risk of esophageal cancer decreases with height
Taller individuals are less likely to develop esophageal cancer and it's precursor, Barrett's esophagus, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.
National Institutes of Health

Contact: Rachel Steigerwald
media@gastro.org
301-272-1603
American Gastroenterological Association

Public Release: 25-Sep-2014
Journal of Thoracic Oncology
New research outlines promising therapies for small cell lung cancer
Two recently published studies by a research team at University Hospitals Case Medical Center Seidman Cancer Center have the potential to advance treatments for small cell lung cell cancer. This aggressive form of lung cancer has seen no treatment advances in 30 years and 'is a disease in urgent need of new drug therapies,' write the study's authors.

Contact: Alicia Reale
alicia.reale@uhhospitals.org
University Hospitals Case Medical Center

Public Release: 25-Sep-2014
Cell
Researchers engineer 'Cas9' animal models to study disease and inform drug discovery
Researchers from the Broad Institute and Massachusetts Institute of Technology have created a new mouse model to simplify application of the CRISPR-Cas9 system for in vivo genome editing experiments. The researchers successfully used the new 'Cas9 mouse' model to edit multiple genes in a variety of cell types, and to model lung adenocarcinoma, one of the most lethal human cancers. A paper describing this new model and its initial applications appears this week in Cell.
National Science Foundation, The Damon Runyon Cancer Research Institute, MIT/Simons Center for the Social Brain, NIH/National Human Genome Research Institute, NIH/National Cancer Institute, NIH/National Institute of Mental Health

Contact: Haley Bridger
hbridger@broadinstitute.org
617-714-7968
Broad Institute of MIT and Harvard

Public Release: 25-Sep-2014
2014 AAO-HNSF Annual Meeting & OTO EXPO
Study: Widespread vitamin D deficiency in thyroidectomy patients
A new study from researchers at Henry Ford Hospital in Detroit finds widespread vitamin D deficiency among patients who undergo a thyroidectomy, potentially putting them at greater risk for developing dangerously low blood calcium levels after surgery.

Contact: Krista Hopson Boyer
khopson1@hfhs.org
313-874-7207
Henry Ford Health System

Public Release: 25-Sep-2014
Cancer Cell
USC researchers discover dual purpose of cancer drug in regulating expression of genes
Keck Medicine of USC scientists have discovered new clues about a drug instrumental in treating a certain blood cancer that may provide important targets for researchers searching for cures.
National Institutes of Health

Contact: Leslie Ridgeway
lridgewa@usc.edu
323-442-2823
University of Southern California - Health Sciences

Showing releases 176-200 out of 1247.

<< < 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 > >>

  Search News Releases

     

 

EurekAlert!